Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy

Abstract Diabetes mellitus treatment currently relies on externally administered insulin, which lacks the precise glucose-responsive regulation of pancreatic β-cells. This study develops a synthetic glucose-responsive gene expression system using repeated glucose-responsive elements (R3G) to regulate insulin production in non-pancreatic cells. The R3G element, derived from carbohydrate response elements (ChoREs) of the liver pyruvate kinase promoter, was incorporated upstream of minimal promoters to create glucose-inducible constructs with low basal activity. Plasmid (pDNA) constructs were generated using the pGM206 backbone containing either reporter genes or a furin-cleavable human insulin cDNA (hsoINSfur). pDNA was delivered into HepG2 cells using the non-viral Glycosaminoglycan-binding Enhanced Transduction (GET) nanoparticle system. Glucose responsiveness was evaluated using Gaussia luciferase (GLuc) assays and a dual secreted reporter system incorporating secreted embryonic alkaline phosphatase (SEAP) as an internal normalisation control. Among the promoters tested, R3G-miniCMV and R3G-SCP1 demonstrated strong glucose-dependent activation while maintaining low basal expression. R3G-miniCMV produced the greatest dynamic range, showing up to ∼24-fold induction under hyperglycaemic conditions (25 mM glucose) relative to hypoglycaemic/glucose-free conditions. Dual-reporter assays confirmed that increased GLuc activity was due to glucose-responsive transcription rather than variations in transfection efficiency or cell viability/metabolism. Replacement of reporter genes with hsoINSfur demonstrated functional insulin secretion, with R3G-containing constructs producing significantly higher C-peptide levels under elevated glucose conditions compared with non-R3G controls. Overall, this study demonstrates that synthetic R3G promoters can confer robust glucose-responsive insulin expression in non-pancreatic cells using a safe non-viral delivery platform, providing a proof-of-concept system for future glucose-regulated insulin gene therapy applications.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-12
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c00749
Primary Topic
Pancreatic function and diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy

Madeleine V. King, Hoda Maher Eltaher, James E. Dixon, An Nisaa Nurzak
Molecular Pharmaceutics
Pancreatic function and diabetes
article

Glucose-Responsive Promoter Engineering for Dynamic Regulation of Insulin Transgene Expression Delivered by Non-Viral Gene Therapy

Madeleine V. King, Hoda Maher Eltaher, James E. Dixon, An Nisaa Nurzak
article en

Abstract

Abstract Diabetes mellitus treatment currently relies on externally administered insulin, which lacks the precise glucose-responsive regulation of pancreatic β-cells. This study develops a synthetic glucose-responsive gene expression system using repeated glucose-responsive elements (R3G) to regulate insulin production in non-pancreatic cells. The R3G element, derived from carbohydrate response elements (ChoREs) of the liver pyruvate kinase promoter, was incorporated upstream of minimal promoters to create glucose-inducible constructs with low basal activity. Plasmid (pDNA) constructs were generated using the pGM206 backbone containing either reporter genes or a furin-cleavable human insulin cDNA (hsoINSfur). pDNA was delivered into HepG2 cells using the non-viral Glycosaminoglycan-binding Enhanced Transduction (GET) nanoparticle system. Glucose responsiveness was evaluated using Gaussia luciferase (GLuc) assays and a dual secreted reporter system incorporating secreted embryonic alkaline phosphatase (SEAP) as an internal normalisation control. Among the promoters tested, R3G-miniCMV and R3G-SCP1 demonstrated strong glucose-dependent activation while maintaining low basal expression. R3G-miniCMV produced the greatest dynamic range, showing up to ∼24-fold induction under hyperglycaemic conditions (25 mM glucose) relative to hypoglycaemic/glucose-free conditions. Dual-reporter assays confirmed that increased GLuc activity was due to glucose-responsive transcription rather than variations in transfection efficiency or cell viability/metabolism. Replacement of reporter genes with hsoINSfur demonstrated functional insulin secretion, with R3G-containing constructs producing significantly higher C-peptide levels under elevated glucose conditions compared with non-R3G controls. Overall, this study demonstrates that synthetic R3G promoters can confer robust glucose-responsive insulin expression in non-pancreatic cells using a safe non-viral delivery platform, providing a proof-of-concept system for future glucose-regulated insulin gene therapy applications.

Molecular Pharmaceutics
University of Nottingham (GB)
Lembaga Pengelola Dana Pendidikan, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, FP7 Ideas: European Research Council
Good health and well-being
Pancreatic function and diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon